Fidarestat

• CAT Number: M115597
• CAS Number: 136087-85-9
• Molecular Formula: C12H10FN3O4
• Molecular Weight: 279.227
• Purity: ≥95%
• Synonyms: SNK 860
• Target: Aldose Reductase
• Storage: -20°C
• IUPAC Name: (2S,4S)-6-fluoro-2/',5/'-dioxospiro[2,3-dihydrochromene-4,4/'-imidazolidine]-2-carboxamide
• InChI: InChI=1S/C12H10FN3O4/c13-5-1-2-7-6(3-5)12(4-8(20-7)9(14)17)10(18)15-11(19)16-12/h1-3,8H,4H2,(H2,14,17)(H2,15,16,18,19)/t8-,12-/m0/s1
• InChIKey: WAAPEIZFCHNLKK-UFBFGSQYSA-N
• SMILES: C1C(OC2=C(C13C(=O)NC(=O)N3)C=C(C=C2)F)C(=O)N

Fidarestat(cas 136087-85-9) is a potent and promising Aldose Reductase Inhibitor. Administration of fidarestat after breakfast was effective in significantly alleviating some symptoms of diabetic polyneuropathy. Long-term treatment with SNK-860 has a beneficial preventive effect on the development of experimental diabetic neuropathy. Fidarestat is also a Promising Drug Targeting Autophagy in Colorectal Carcinoma.

Reference

1:Aldose Reductase Inhibitor Fidarestat as a Promising Drug Targeting Autophagy in Colorectal Carcinoma: a Pilot Study. Pandey S.Asian Pac J Cancer Prev. 2015;16(12):4981-5. PMID: 26163626 Free Article
2:LC-MS-MS Characterization of Forced Degradation Products of Fidarestat, a Novel Aldose Reductase Inhibitor: Development and Validation of a Stability-Indicating RP-HPLC Method. Talluri MV, Khatoon L, Kalariya PD, Chavan BB, Ragampeta S.J Chromatogr Sci. 2015 Oct;53(9):1588-96. doi: 10.1093/chromsci/bmv061. Epub 2015 May 25. PMID: 26014964
3:Plasma protein binding, pharmacokinetics, tissue distribution and CYP450 biotransformation studies of fidarestat by ultra high performance liquid chromatography-high resolution mass spectrometry. Borkar RM, Bhandi MM, Dubey AP, Nandekar PP, Sangamwar AT, Banerjee SK, Srinivas R.J Pharm Biomed Anal. 2015 Jan;102:386-99. doi: 10.1016/j.jpba.2014.10.008. Epub 2014 Oct 19. PMID: 25459938
4:X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity. Ruiz FX, Cousido-Siah A, Mitschler A, Farrés J, Parés X, Podjarny A.Chem Biol Interact. 2013 Feb 25;202(1-3):178-85. doi: 10.1016/j.cbi.2012.12.013. Epub 2013 Jan 4. PMID: 23295227
5:Amelioration of acute kidney injury in lipopolysaccharide-induced systemic inflammatory response syndrome by an aldose reductase inhibitor, fidarestat. Takahashi K, Mizukami H, Kamata K, Inaba W, Kato N, Hibi C, Yagihashi S.PLoS One. 2012;7(1):e30134. doi: 10.1371/journal.pone.0030134. Epub 2012 Jan 12. PMID: 22253906 Free PMC Article
6:Evaluation of the aldose reductase inhibitor fidarestat on ischemia-reperfusion injury in rat retina. Obrosova IG, Maksimchyk Y, Pacher P, Agardh E, Smith ML, El-Remessy AB, Agardh CD.Int J Mol Med. 2010 Jul;26(1):135-42. PMID: 20514433 Free PMC Article
7:Aldose reductase inhibitor fidarestat attenuates leukocyte-endothelial interactions in experimental diabetic rat retina in vivo. Hattori T, Matsubara A, Taniguchi K, Ogura Y.Curr Eye Res. 2010 Feb;35(2):146-54. doi: 10.3109/02713680903447918. PMID: 20136425
8:The aldose reductase inhibitor fidarestat suppresses ischemia-reperfusion-induced inflammatory response in rat retina. Agardh CD, Agardh E, Obrosova IG, Smith ML.Pharmacology. 2009;84(5):257-63. doi: 10.1159/000241733. Epub 2009 Sep 24. PMID: 19776662
9:Charge density and electrostatic interactions of fidarestat, an inhibitor of human aldose reductase. Fournier B, Bendeif el-E, Guillot B, Podjarny A, Lecomte C, Jelsch C.J Am Chem Soc. 2009 Aug 12;131(31):10929-41. doi: 10.1021/ja8095015. PMID: 19594152
10:Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal oxidative-nitrosative stress, glial activation, and apoptosis. Drel VR, Pacher P, Ali TK, Shin J, Julius U, El-Remessy AB, Obrosova IG.Int J Mol Med. 2008 Jun;21(6):667-76. PMID: 18506358 Free PMC Article